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Introduction
A number of transfection methods and vector systems have been developed to deliver exogenous genes into the liver, but all have limitations. For example, retroviral vectors have been used for gene delivery into rat livers in combination with a partial hepatectomy, [1] [2] [3] but transfection efficiency was relatively low and gene expression was observed in 5-15% of hepatocytes. Adenoviral vectors appear to be more efficient for gene transduction in hepatocytes in vivo, 4 but these vectors may cause cytotoxicity due to the highly immunogenic properties of adenoviral proteins. Therefore, adenoviral vectors can be used only for transient gene expression. [4] [5] [6] However, it has been recently reported that a new type of adenoviral vector has succeeded in preventing antiviral host immune response. 7 Recently, a new gene transduction method using liposome containing hemagglutinating virus of Japan (HVJliposome) has been developed, 8 and human insulin and hepatitis B virus genes were transiently expressed in rat hepatocytes in vivo by portal injection. 9, 10 In the present study, we isolated a caudal lobe of rat liver from systemic circulation and transduced the Escherichia coli ␤-galactosidase (␤-gal) gene by direct injection into the liver parenchyma. 11, 12 It was found that more than 60% of hepatocytes expressed ␤-gal in the transfected rat liver by this method. Furthermore, we found that the repetitive in vivo transfections prolonged ␤-gal gene expression in rat liver, and did not induce cytotoxic T lymphocyte (CTL) activity against the transfected hepatocytes.
Results
Expression of ␤-gal in hepatocytes by targeted transfection by HVJ-liposome The ␤-gal-HVJ-liposome was delivered into the target caudal liver tissue wihout dissipation into the systemic circulation, because the hepatic vein and portal vein as well as hepatic artery were temporarily ligated by clamping the neck of the caudal lobe with vascular clips. The expression of ␤-gal mRNA was investigated by RT-PCR using total RNA extracted from caudal lobe 3 days after direct injection of ␤-gal-HVJ-liposome. As shown in Figure 1a , a 247 bp RT-PCR fragment of ␤-gal transcript was detected in livers transfected with ␤-gal-HVJ-liposome (lanes 2 and 3, Figure 1a ). The presence of ␤-gal protein in these liver tissues was confirmed by Western blot analysis. A 116 kDa ␤-gal protein was detected in the liver homogenates of caudal lobes that were transfected with ␤-gal-HVJ-liposome (lanes 2 and 3, Figure  1b ), but not in that of PBS-injected caudal liver (lane 4, Figure 1b ).
The expression of ␤-gal protein in transfected liver was examined histologically by staining with X-gal. The mean percentage of ␤-gal-positive hepatocytes in the transfected liver was 66.0 ± 12.3% (mean ± s.d., n = 6) when examined 3 days after transfection (Figure 2a) . It is of note that more than 20% of hepatocytes expressed ␤-gal 28 days after the single in vivo transfection (Figure 2a) . In contrast, the number of ␤-gal-positive hepatocytes in rats transfected via the portal vein was 30.1 ± 10.1% (n = 4) 3 days after injection, and rapidly decreased to 3.5 ± 1.1% (n = 3) within 28 days of injection (Figure 2a) . Figure 2b demonstrates typical ␤-gal staining of a cryostat section of caudal lobe 3 days after the targeted transfection using HVJ-liposome. More than 80% of hepatocytes demonstrated blue-staining of ␤-gal in this transfected liver tissue (Figure 2b × 100, c × 200), whereas a cryostat liver section from a control caudal lobe tissue injected with PBS did not demonstrate any staining (Figure 2d ). Of note, hematoxylin and eosin staining of paraffin sections of rat livers transfected with ␤-gal-HVJliposome showed normal liver histology and no evaluation of serum glutamic-pyruvic transaminase (GPT) activity was found after transfection (data not shown).
Repetitive in vivo transfections
In order to investigate if repetitive in vivo transfections are feasible, we tested multiple injections of ␤-gal-HVJliposome into rat liver. Three days after the final transfection, rats were killed and liver tissues were obtained. The percentage of ␤-gal-positive hepatocytes were 71.6 ± 6.5% (n = 4) after the second transfection, and 77.9 ± 5.8% (n = 4) after the third transfection ( Figure 3 ). The livers of these animals were histologically normal and no hepatocyte death or lymphocyte infiltration was observed (data not shown).
Antibody and CTL response to HVJ-liposome
Antibody to HVJ-liposome was found in the sera of the majority of rats with the highest titer detected at 14 days after transfection with ␤-gal-HVJ-liposome (Figure 4a ). Of note, the highest antibody titer detected in rat serum was less than 1:1 × 10 4 dilution of the serum antibody titer in HVJ-immunized rabbit (data not shown). CTL response to HVJ-liposome-transfected hepatocytes and TNP-modified hepatocytes are shown in Figure 4b . TNPprimed CTL demonstrated a strong cytotoxicity against TNP-modified hepatocyte targets but not against unmodified target hepatocytes. In contrast, HVJ-liposome-primed lymphocyte did not produce cytotoxicity to the autologous hepatocytes that were transfected with ␤-gal-HVJ-liposome in vivo.
Discussion
Retrovirus, 1,2 asialoglycoprotein conjugated with poly-llysine 11 and cationic lipid 13 have been previously employed as gene delivery approaches to the liver, but gene expression using these vectors was transient. Although a partial hepatectomy increased transfection efficiency and prolonged gene expression by retrovirus 1, 2 or asialoglycoprotein-mediated transfection in an animal model system, 11 a hepatectomy is not feasible in human gene therapy. Previous recombinant adenoviruses stimulate a humoral immune response and produce neutralizing antibodies when they are used as in vivo transfection vehicles.
14 Recently, a new type of recombinant adenovirus was reported. Adenovirus early region 3 (E3) was inserted into recombinant adenovirus and was successful in preventing antiviral host-immune response. 7 In this report, we demonstrate that a high gene transduction rate was achieved by direct injection of HVJ-liposome into a target liver that was temporarily isolated from systemic circulation. In addition, the level of ␤-gal expression in the transfected liver was not inhibited by prior transfections by HVJ-liposome. Therefore, persistent gene expression was achieved by repetitive in vivo transfections.
Sieve plates formed by extensions of endothelial cells which separate sinusoidal blood from the space of Disse and hepatocytes of rat livers contain multiple fenestrae or pores. The diameter of the fenestrae is reported to be about 175 nm in the periportal area. 15 Enlargement of fenestrae diameter has been reported after perfusion with pressure. 16 Although HVJ-liposome is about 400 nm in diameter, 17 the enlargement of fenestrae may contribute to the admission of HVJ-liposome to the parenchymal cells in our method.
A general problem in gene transduction is degradation of the transfected gene. In this regard, exogenous macromolecules can be delivered into the cell by pinocytosis or receptor-mediated endocytosis, but the internalized molecules usually traffic into the lysosome pathway where they are degraded. 18 In contrast, macromolecules encapsulated in HVJ-liposomes appear to be introduced directly into cytoplasm by the fusion of viral protein and cell membrane, thereby bypassing the lysosomal pathway. Furthermore, the introduced DNA is efficiently translocated into the nucleus with the help of HMG-1 nuclear proteins. transient, and the antibody titers were substantially lower than those from rabbit subcutaneously immunized with HVJ. CTLs are a central component of the cellular immune response to acute viral infection 19 and are important for the elimination of virus and infected cells. In our study, HVJ-liposome-transfected rats did not generate CTL activity to hepatocytes transfected by HVJ-liposome.
There are several possible explanations for this finding. The number of HVJ-liposome particles which fuse to a hepatocyte (multiplicities of infection) is low (1-5 HVJ particles per cell 20 ), thereby leading to a low load of total viral protein in the hepatocytes. In addition, MHC class I molecules may not be able to present HVJ to initiate CTL response because UV-irradiated HVJ does not replicate and synthesize viral proteins in the cell.
The other advantages of HVJ-liposome for in vivo gene transduction are as follows. First, HVJ are replicationdefective and safe, since they are inactivated by UV irradiation before use. Second, fusion of viral and plasma membranes occurs quickly (within 1-2 min after binding). 21 Third, liposomes composed of anionic lipid are able to hold 500-1000 molecules of plasmid DNA per liposome. 17 These features seem to be important for a high transduction rate in vivo.
Experimental applications include the use of this method for the study of liver diseases, for example, making an acquired liver disease animal model such as hepatitis and testing the expression of a DNA construct in vivo by introducing several kinds of genes. On the other hand, this method of gene transduction to the liver has limitations; it needs surgical treatment to inject HVJ-liposome directly to the liver. Administration of HVJ-liposome into systemic circulation resulted in low efficacy of expression in the liver.
Figure 4 Host immune-response to HVJ-liposome. (a) Serum anti-HVJliposome antibody. (b) CTL responses of TNP-primed rat spleen cells to TNP-modified hepatocyte targets and of HVJ-primed rat spleen cells to HVJ-liposome-transfected hepatocyte targets.
We have demonstrated that HVJ-liposome-mediated gene transfer into the liver produced a persistent expression of the transfected gene. This approach is surgically feasible in human gene therapies which may be useful for the treatments of various hepatic diseases.
Materials and methods
Preparation of HVJ-liposome HVJ-liposomes were prepared as described previously. 22 Briefly, phosphatidylserine, phosphatidylcholine and cholesterol were mixed in a weight ratio of 1:4.8:2. This lipid mixture (1 mg) and plasmid DNA (20-40 g) which was previously complexed with 6-12 g of high-mobility group-1 (HMG-1) nonhistone chromosomal protein purified from calf thymus, were sonicated to form liposomes and then mixed with UV irradiated HVJ. Free HVJ was removed from the HVJ-liposomes by sucrose density gradient centrifugation. The expression vector used in this study was psV-␤-galactosidase vector (␤-gal) (Promega, Madison, WI, USA), in which bacterial lacZ gene was driven by the SV40 early promotor and enhancer.
Animals and in vivo transfection
Six-week-old male Wistar rats were used in this study. After the animals were anesthetized with ether, the neck of the caudal lobe was temporarily ligated for approximately 10 min with vascular clips to interrupt hepatic vein and portal vein as well as hepatic artery circulation, then the caudal liver was transfected with ␤-gal gene by direct liver injection of HVJ-liposome. Control rats were injected with phosphate-buffered saline (PBS) using the same procedures.
Repetitive in vivo transfections
To investigate whether or not the efficiency of gene transduction is affected by the preceding HVJ-liposome transfections, HVJ-liposome-␤-gal gene complex was injected into the caudal lobe of rats that were previously transfected in the right lobes at −14 days (n = 4) or at −28 days and −42 days (n = 4). Rats were killed 3 days after the transfection of caudal lobe and the expression of ␤-gal in the hepatocytes was compared with that of rats without the repetitive transfections (n = 6).
Bacterial ␤-gal staining One-half of each transfected liver was snap-frozen in liquid nitrogen and used for the RNA and protein extraction. The remaining half was fixed in situ by perfusion of a 1% glutaraldehyde solution. The fixed liver blocks of 5 mm thickness were then incubated overnight at 4°C in phosphate-buffered saline (PBS) containing 20% sucrose, and frozen on dry ice. The cryostat sections of these liver tissues were treated with X-gal (Nakarai, Kyouto, Japan) to detect ␤-gal and counterstained with hematoxylin. The efficiency of gene transduction was evaluated by the presence of blue staining of hepatocytes by X-gal in five random high-power (× 100) fields.
Western blot analysis
The expression of ␤-gal protein in the transfected liver was also investigated by Western blot analysis as previously reported. 23 In brief, 10 g of liver homogenate derived from snap-frozen tissue was separated by 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred on to polyvinylidene fluoride (PVDF) membrane (Micron Separations, Westborough, MA, USA). The ␤-gal protein was detected by incubation with rabbit anti-␤-gal antibody (Promega) diluted in PBS containing 1% gelatine and casein for 1 h at room temperature followed by anti-rabbit IgG-peroxidase. The immunoreactive proteins were visualized with a chemiluminescent system (Amersham, Little Chalfont, UK) and exposed to radiographic film.
Detection of ␤-gal RNA The expression of ␤-gal mRNA in rat liver was examined by reverse transcription (RT) of total RNA followed by PCR analysis (RT-PCR). RNA extraction and RT-PCR were performed as previously described. 10 cDNA was synthesized from 2 g of total RNA and the amplification cycles of PCR were 94°C for 1 min, 55°C for 1 min and 72°C for 1 min. The PCR products were separated by electrophoresis on a 1.5% agarose gel after 35 cycles and transferred to Hybond-N + nylon membranes (Amersham). Southern blot hybridization was performed using 3Ј-oligo labelling and detection system (Amersham). The primers used for amplification of ␤-gal gene were a sense primer, 5Ј-CTACACCAA CGTAACCTATCCC-3Ј and an antisense primer, 5Ј-TTCTCCGGCGCGTAAAAATGCG-3Ј, which yielded a 247-bp fragment of the ␤-gal gene. 24 Total RNA extracted from Hep1a cells (mouse hepatoma cell line) transfected with ␤-gal gene was used as positive control of ␤-gal mRNA.
Detection of anti-HVJ-liposome antibody Sera were collected from tail veins of rats. The presence of antibody to HVJ-liposome was determined by antibody capture assay. 25 HVJ-liposome was bound to the bottom of polyvinylchloride microtiter plate wells by incubating 100 l of HVJ-liposome solution (5000 hemagglutinating units/ml) at 40°C for 12 h. After washing, the nonspecific protein binding sites of each well was blocked with PBS containing 3% BSA. Serum samples (50 l per well) were then incubated in each well for 1 h followed by incubation with 45 l of anti-rat IgG antibody conjugated with alkaline phosphatase (ICN Pharmaceuticals, Costa Mesa, CA, USA) for 1 h. After washing the plate with Tris-buffered saline (TBS) containing 0.05% of Tween 20, bound antibodies were quantified by chemiluminescence system (BioRad, Hercules, CA, USA) by spectrophotometer at 405 nm. Sera collected from a rabbit that was immunized subcutaneously with HVJ and adjuvant were used as a positive control for anti-HVJ antibody.
CTL assay
To determine if in vivo transfection by HVJ-liposome induces a cellular immune response against transfected hepatocytes, we investigated CTL response to hepatocytes that were transfected by HVJ-liposome (HVJ-CTL). CTL response to trinitrophenyl (TNP)-modified hepatocytes (TNP-CTL) was used as a positive control for CTL response. 26, 27 Rats were immunized subcutaneously with HVJ-liposome containing 20 g of ␤-gal gene. Seven days later, splenocytes and hepatocytes were prepared after splenectomy and partial hepatectomy as previously described. 28, 29 The primary rat hepatocytes were cultured overnight in 24-well flat-bottom plastic plates and were transfected with ␤-gal gene by incubation with HVJ-liposome containing 1 g of ␤-gal gene for 30 min. These transfected rat hepatocytes (1 × 10 6 /ml) were irradiated (20 Gy) and were cocultured with autologous rat splenocytes (5 × 10 6 /ml) to produce HVJ-CTL in vitro. 26 After 5 days of culture, spleen cells were harvested and CTL activity was examined by a 51 Cr-release assay using autologous rat hepatocytes which were transfected in vivo with HVJ-liposome containing 20 g of ␤-gal gene by direct injection into the caudal lobe immediately after the partial hepatectomy.
To generate TNP-CTLs in vitro, spleen cells and hepatocytes were prepared from rats immunized subcutaneously with 1 ml of 10 m 2,4,6-trinitrobenzen sulfonic acid 7 days before. The spleen cells (5 × 10 6 /ml) were then cultured with autologous hepatocytes (1 × 10 6 /ml) that were previously incubated with 10 mm of TNP for 10 min (TNP-modified hepatocytes) and were irradiated (20 Gy). Five days later, rats were killed and the cytotoxicity of TNP-primed CTL was tested using TNP-modified or unmodified autologous hepatocytes as target cells.
